Shree Ganesh Remedies Limited
BSE: SGRL
Prev Close
568.55
Open Price
560.5
Volume
3,544
Today Low / High
560.5 / 588
52 WK Low / High
560 / 950
Range
547 - 605
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 575.85, reflecting a change of 7.3 (1.28397%). The expected target range on the BSE is 547 - 605. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.
Shree Ganesh Remedies Limited Graph
Shree Ganesh Remedies Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Shree Ganesh Remedies Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 575.85, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 575.85 | 581.61 | 523.45 - 639.77 |
| 587.37 | 469.89 - 704.84 | ||
| 593.13 | 415.19 - 771.06 | ||
| Bearish Scenario | 575.85 | 570.09 | 513.08 - 627.10 |
| 564.33 | 451.47 - 677.20 | ||
| 558.57 | 391.00 - 726.15 |
Overview of Shree Ganesh Remedies Limited
ISIN
INE414Y01015
Industry
Medical - Pharmaceuticals
Vol.Avg
10,555
Market Cap
7,390,977,165
Last Dividend
0
Official Website
IPO Date
DCF Diff
1,011.01
DCF
-435
Financial Ratios Every Investor Needs
Stock Dividend of SGRL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2023-09-07 | September 07, 23 | 0.5 | 0.5 | 2023-09-07 | 2023-09-25 | |
| 2022-09-15 | September 15, 22 | 0.49646 | 0.49646 | 2022-09-16 | 2022-10-28 | |
| 2021-09-08 | September 08, 21 | 1.44799 | 1.7376 | 2021-09-11 | 2021-10-18 | |
| 2020-09-01 | September 01, 20 | 1.11274 | 1.4894 | 2020-09-02 | 2020-10-19 | |
| 2019-08-22 | August 22, 19 | 0.92729 | 1.2411 | 2019-08-23 | 2019-09-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 108.60 Cr | 35.87 Cr | 72.72 Cr | 0.6697 | 0.00 Cr | 0.00 Cr | 62.60 Cr | 23.07 Cr | 17.96 | 39.21 Cr | 0.2124 |
| 2024-03-31 | 125.90 Cr | 58.48 Cr | 67.42 Cr | 0.5355 | 0.02 Cr | 0.94 Cr | 57.25 Cr | 28.11 Cr | 22.34 | 44.88 Cr | 0.2233 |
| 2023-03-31 | 90.22 Cr | 47.16 Cr | 43.06 Cr | 0.4772 | 2.08 Cr | 0.66 Cr | 20.59 Cr | 17.02 Cr | 13.86 | 26.49 Cr | 0.1887 |
| 2022-03-31 | 71.29 Cr | 37.05 Cr | 34.24 Cr | 0.4802 | 1.98 Cr | 0.55 Cr | 15.33 Cr | 13.40 Cr | 11.08 | 18.47 Cr | 0.1880 |
| 2021-03-31 | 49.08 Cr | 22.02 Cr | 27.06 Cr | 0.5514 | 0.76 Cr | 0.47 Cr | 11.45 Cr | 9.75 Cr | 8.07 | 15.80 Cr | 0.1987 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 10.03 Cr | 191.94 Cr | 46.79 Cr | 145.1552 Cr | 38.38 Cr | 28.35 Cr | 22.02 Cr | 103.31 Cr | 0.00 Cr | 0.00 Cr | 0.08 Cr | 16.1824 Cr |
| 2024-03-31 | 15.85 Cr | 170.94 Cr | 48.84 Cr | 122.0983 Cr | 36.45 Cr | 20.60 Cr | 24.99 Cr | 99.11 Cr | 0.00 Cr | 0.00 Cr | 0.09 Cr | 18.6808 Cr |
| 2023-03-31 | 8.65 Cr | 143.83 Cr | 54.90 Cr | 88.9372 Cr | 33.51 Cr | 24.86 Cr | 18.18 Cr | 76.45 Cr | 5.85 Cr | 0.00 Cr | 0.50 Cr | 23.7400 Cr |
| 2022-03-31 | 3.88 Cr | 77.02 Cr | 15.44 Cr | 61.5739 Cr | 0.00 Cr | -3.88 Cr | 13.64 Cr | 29.82 Cr | 0.00 Cr | 0.00 Cr | 1.16 Cr | 15.0397 Cr |
| 2021-03-31 | 3.47 Cr | 60.60 Cr | 10.59 Cr | 50.0032 Cr | 0.21 Cr | -3.25 Cr | 12.71 Cr | 20.29 Cr | 3.72 Cr | 0.00 Cr | 1.61 Cr | 10.1878 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 30.6640 Cr | -35.6581 Cr | -1.0883 Cr | 7.4689 Cr | -5.9070 Cr | 9.9465 Cr | -23.1951 Cr | 23.0684 Cr | 0.9623 Cr | 0.0000 Cr | 2.9702 Cr |
| 2024-03-31 | 30.4483 Cr | -33.0091 Cr | 9.8408 Cr | -0.6897 Cr | 7.2033 Cr | 15.8535 Cr | -31.1380 Cr | 28.1080 Cr | 3.6952 Cr | -0.6256 Cr | -6.8122 Cr |
| 2023-03-31 | 17.0114 Cr | -53.5748 Cr | 41.3305 Cr | -34.5718 Cr | 4.7670 Cr | 8.6502 Cr | -51.5832 Cr | 22.5843 Cr | 30.9324 Cr | -0.6003 Cr | -4.5347 Cr |
| 2022-03-31 | 13.4167 Cr | -11.9131 Cr | -1.0867 Cr | -1.9110 Cr | 0.4169 Cr | 3.8832 Cr | -15.3277 Cr | 18.0052 Cr | 0.5221 Cr | -1.6088 Cr | -0.9278 Cr |
| 2021-03-31 | 3.3115 Cr | -0.9422 Cr | -0.6569 Cr | 3.3025 Cr | 1.7124 Cr | 3.4663 Cr | -0.0090 Cr | 12.9495 Cr | -0.4979 Cr | 0.0000 Cr | -7.2093 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 24.43 Cr | 5.84 Cr | 18.59 Cr | 0.7608 | 15.90 Cr | 6.59 Cr | 5.13 | 9.84 Cr | 0.2697 |
| 2024-12-31 | 27.05 Cr | 8.40 Cr | 18.65 Cr | 0.6896 | 7.20 Cr | 5.42 Cr | 4.22 | 10.61 Cr | 0.2005 |
| 2024-09-30 | 32.33 Cr | 18.08 Cr | 14.25 Cr | 0.4408 | 8.89 Cr | 6.41 Cr | 4.97 | 11.50 Cr | 0.1981 |
| 2024-06-30 | 24.78 Cr | 12.76 Cr | 12.02 Cr | 0.4850 | 6.11 Cr | 4.65 Cr | 3.62 | 8.12 Cr | 0.1876 |
| 2024-03-31 | 37.33 Cr | 17.74 Cr | 19.59 Cr | 0.5249 | 15.07 Cr | 11.99 Cr | 10.00 | 18.26 Cr | 0.3212 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 10.03 Cr | 18.26 Cr | 28.29 Cr | 22.27 Cr | 22.02 Cr | 77.58 Cr | 103.31 Cr | 191.94 Cr | 46.79 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 21.27 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -133.14 Cr |
| 2024-09-30 | 14.65 Cr | 6.64 Cr | 21.29 Cr | 31.78 Cr | 17.86 Cr | 73.30 Cr | 99.40 Cr | 178.30 Cr | 45.17 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 20.92 Cr | 0.00 Cr | 0.00 Cr | 20.92 Cr | 0.00 Cr | 0.00 Cr | -122.10 Cr |
| 2024-03-31 | 16.26 Cr | 4.66 Cr | 20.92 Cr | 20.33 Cr | 24.99 Cr | 70.20 Cr | 97.11 Cr | 170.94 Cr | 48.84 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 6.59 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 5.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 6.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 4.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 11.99 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2021-11-01 | November 01, 21 | 6:5 |
| 2020-10-06 | October 06, 20 | 29:26 |
Similar Stocks: Medical - Pharmaceuticals
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| MedPlus Health Services Limited | MEDPLUS | ₹915.25 | ₹109,595,165,155.00 | ₹130,411.00 |
Key Executives
Gender: male
Year Born: 1996
Gender: male
Year Born: 1963
Gender: male
Year Born: 1993
Gender: male
Year Born: 1992
FAQs about Shree Ganesh Remedies Limited
The CEO is Chandulal Manubhai Kothia.
The current price is ₹575.85.
The range is ₹560-950.
The market capitalization is ₹739.10 crores.
The P/E ratio is 32.07.
The company operates in the Healthcare sector.
Overview of Shree Ganesh Remedies Limited (ISIN: INE414Y01015) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹739.10 crores and an average daily volume of 10,555 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.